期刊文献+

急性髓性白血病178例患者的细胞遗传学特征 被引量:7

The cytogenetic characteristics of 178 acute myeloid leukemia patients
原文传递
导出
摘要 目的 探讨急性髓性白血病(AML)患者的细胞遗传学特征.方法 采用骨髓短期培养和G显带技术对178例AML患者进行染色体核型分析.结果 178例患者中,171例有足够可供分析的中期分裂象.171例患者异常克隆检出率74.9%.其中27例患者为骨髓增生异常综合征(MDS)继发AML,其异常克隆榆出率为92.6%,在其余144例原发AML中异常克隆检出率为71.5%,MDS继发AML异常克隆检出率明显高于原发AML患者.171例患者中预后良好核型占24.0%,预后中等核型占46.8%,预后不良核型占29.2%.在预后良好核型中以t(15;17)为多;在预后中等核型中以正常核型为主;在预后不良核型中以复杂异常核型为主,复杂核型的异常克隆中常含有-5/5q-、-7/7q-等具有不良预后的异常克隆.老年组75例患者中,预后良好、预后中等及预后不良核型分别为16.0%、48.0%及36.O%,年轻组96例患者中分别为30.2%、45.8%及24.0%.老年患者预后良好核型比例低于年轻患者.MDS继发AML患者预后不良核型比例及单体核型比例均高于原发AML患者(P值均〈0.001).结论 t(15;17)、正常核型、复杂核型分别是AML最常见的预后良好核型、预后巾等核型及预后不良核型.MDS继发的AML及老年AML患者染色体核型预后不良. Objective To explore the cytogenetic characteristics of acute myeloid leukemia(AML) patients.Methods The karyotype analysis was performed in 178 AML using the short-term culture of bone marrow cell and G-banding technique.Results Among the 178 patients,171 had enough metaphases for analysis and 128(74.9%)had clonal karyotypic abnormalities.Twenty-seven patients were secondary to myelodysplastic syndrome (MDS-AML),with 25 (92.6%) patients carrying clonal karyotypic abnormalities.Among the remaining 144 patients of de novo AML,103(71.5%)had clonal karyotypic abnormalities.The rate of abnormal clonal karyotype was higher in MDS-AML than that of de novo AML (P=0.021).Among the 171 patients,41(24.0%)were in favorable risk group,80(46.8%)in intermediate risk group and 50(29.2%)in adverse risk group.t(15;17)was the most common chromosomal aberration.The maiority intermediate risk chromosomal aberration was;normal karyotype.The most common cytogenetic abnormality among adverse group was a complex karyotype.Adverse cytogenetic aberrations,such as -5/5q-,-7/7q-,frequently occurred in conjunction with one another as part of a complex karyotype.Totally 75 patients were 60 years or older,among them,16.0%were in favorable risk group,48.0%in intermediate risk group and 36.0%in adverse risk group.Among 96 younger patients,30.2%were in favorable risk group.45.8%in intermediate risk group and 24.0%in adverse risk group.The rate of favorable risk chromosomal aberration was lower in elder patients than in younger(P=0.03 1).The rate of adverse risk chromosomal aberration and the rate of monosomal karyotype were higher in MDSAML than in de novo AML patients(P〈0.001).Conclusions The most common favorable,intermediate and adverse chromosomal aberrations were t(15;17),normal karyotype and complex karyotype respectively.The karyotype was poor in MDS-AML and elder AML patients.
出处 《中华内科杂志》 CAS CSCD 北大核心 2011年第8期683-686,共4页 Chinese Journal of Internal Medicine
关键词 白血病 粒细胞 急性 核型分析 细胞遗传学 骨髓增生异常综合征 Leukemia,myelocytic,acute Karyotyping Cytogeneties Myelodysplastic syndromes
  • 相关文献

参考文献11

  • 1Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 2010, 116 : 354-365.
  • 2S|ovak ML, Kopecky KJ, Cassileth PA, et al. Karyotype analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 2000, 96: 4075- 4083.
  • 3Grimwade D, Walker H, Harrison G, et al. The predictive valueof hierachical cytogenetic classification in older adults with acute myeloid leukemia (AML) : analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood, 2001, 98: 1312-1320.
  • 4Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001 : 75-115.
  • 5Shaffer LG, Tommerup N. ISCN (2005). An International System for Human Cytogenetic Nomenclature. Switzerland: Karger Baselpublication, 2005 : 55-83.
  • 6Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 2008, 26: 4791-4797.
  • 7Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic eytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998, 92: 2322-2333.
  • 8陈赛娟,曹琪,马志贵,苏欣莹,熊树民,叶菁,王振义,李秀松,沈志祥,张芬琴,孙关林,方智雯,欧阳仁荣,朱学宏,应大明,顾龙君,陈竺.急性非淋巴细胞白血病的细胞遗传学及其预后意义[J].中华血液学杂志,1996,17(2):61-63. 被引量:27
  • 9卢瑞南,李建勇.Fms样酪氨酸激酶3突变与恶性血液病[J].中华内科杂志,2005,44(2):157-158. 被引量:1
  • 10孙超,张苏江,李建勇,沈云峰.急性髓系白血病预后相关的分子标志[J].中国实验血液学杂志,2009,17(4):1083-1087. 被引量:3

二级参考文献44

  • 1Haas K, Kundi M, Sperr WR, et al. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVIl in 266 patients with de novo AML: EVIl and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer,2008 ;47:288 - 298.
  • 2Lugthart S, Van Drunen E, Van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVIl over-expression and chromosome 3q26 abnormalities underestimated. Blood,2008 ; 111:4329 -4337.
  • 3Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol,2005 ;23:9234 -9242.
  • 4Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol, 2007 ;25:3337 - 3343.
  • 5Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol, 2006 ;24:790 - 797.
  • 6Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B ( CALGB ) study. Blood, 2008 ; 111:5371 -5379.
  • 7Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expres- sion as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood, 2006; 108: 3898- 905.
  • 8Carella C, Bonten J, Sirma S, et al. MN1 overexpression is an important step in the development of inv ( 16 ) AML. Leukemia, 2007 ;21 : 1679 - 1690.
  • 9Heuser M, Argiropoulos B, Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in AML patients. Blood ,2007 ; 110 : 1639 - 1647.
  • 10Paschka P, Marcucci G, mutations independently cytogenetically normal leukemia group B study. Ruppert AS, et al. Wilms' tumorlgene predict poor outcome in adults with acute myeloid leukemia: a cancer and J Clin Oncol, 2008 ;26:4595 - 4602.

共引文献28

同被引文献81

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部